Golden
Kymab

Kymab

Kymab is a biopharmecutical company developing human antibody based therapies.

Kymab is a biopharmecutical company founded in 2010. The company was started in parntership by Professor Allan Bradley and Dr Glenn A Friedrich. Kymab is developing human antibody based therapies using embryonic stem cell technology.

Timeline

May 2014

Kymab raises a $40,000,000 series B round from Bill & Melinda Gates Foundation and Wellcome Trust.

July 12, 2010

Kymab raises a $30,400,000 series A round from Wellcome Trust.

Funding rounds

Funding round
Funding round amount (USD)
Funding type
Funding round date
Investment
2 Results
Page 1 of 1
Results per page:
Powered by Golden Research Engine

People

Name
Role
LinkedIn

Dr Glenn A Friedrich

Co-Founder



Professor Allan Bradley

Co-founder



Further reading

Title
Author
Link
Type
Date

Complete humanization of the mouse immunoglobulin loci enables efficient therapeutic antibody discovery

E Lee, Qi Liang, Hanif Ali, Luke Bayliss, Alastair Beasley, Tara Bloomfield-Gerdes, Laura Bonoli, Richard Brown, Jamie Campbell, Adam Carpenter, Sara Chalk, Alison Davis, Nick England, Alla Fane-Dremucheva, Bettina Franz, Volker Germaschewski, Helen Holmes, Steve Holmes, Ian Kirby, Miha Kosmac, Anais Legent, Hui Lui, Anais Manin, Siobhan O'leary, Jemima Paterson, Rocco Sciarrillo, Anneliese Speak, Dominik Spensberger, Laura Tuffery, Nikole Waddell, Wei Wang, Sophie Wells, Vivian Wong, Andrew Wood, Michael J Owen, Glenn A Friedrich, Allan Bradley

Journal

April 4, 2014

Documentaries, videos and podcasts

Title
Date
Link





Companies

Company
CEO
Location
Products/Services